MYLOTARG 5 mg

Mylotarg (gemtuzumab ozogamicin) is a CD33-directed antibody and cytotoxic drug conjugate used for:

• treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older.
• treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.

Recommended Dosage:
Recommended Dose for Newly Diagnosed De Novo CD33-positive AML (Combination Regimen):

• Adults: The recommended dose in adults is 3 mg/m2. A treatment course including Mylotarg in combination therapy for adults with newly diagnosed de novo CD33-positive AML consists of 1 induction cycle and 2 consolidation cycles. For the induction cycle, the recommended dose is 3 mg/m2 (up to one 4.5 mg vial) on Days 1, 4, and 7 together with daunorubicin and cytarabine. For patients requiring a second induction cycle, do not administer this medicine during the second induction cycle. For the consolidation cycles, the recommended dose is 3 mg/m2 on Day 1 (up to one 4.5 mg vial) together with daunorubicin and cytarabine.
  
  
• Pediatric Patients 1 Month and Older: The recommended dose in pediatric patients aged 1 month and older is 3 mg/m2 for patients with body surface area (BSA) greater than or equal to 0.6 m2 and 0.1 mg/kg for patients with BSA less than 0.6 m2. For Induction 1, Mylotarg is given once, along with standard chemotherapy. No dose is given in the second induction cycle. No dose is given in the first or third intensification cycles. For Intensification 2, the dose is given once, along with standard chemotherapy.

Recommended Dose for Newly Diagnosed CD33-positive AML (Single-agent Regimen):

• As a single agent, the treatment course for adults with newly diagnosed CD33-positive AML generally consists of 1 induction cycle and up to 8 cycles of continuation therapy.
• For the induction cycle, the recommended dose is 6 mg/m2 (not limited to one 4.5 mg vial) as a single agent on Day 1, and 3 mg/m2 (not limited to one 4.5 mg vial) on Day 8.
• For continuation, the recommended dose is 2 mg/m2 (not limited to one 4.5 mg vial) as a single agent on Day 1 every 4 weeks.

Relapsed or Refractory CD33-positive AML (Single-agent Regimen):

• The recommended dose as a single agent for treatment for adults and pediatric patients aged 2 years and older with relapsed or refractory CD33-positive AML is 3 mg/m2 (up to one 4.5 mg vial) on Days 1, 4, and 7. Treatment in the relapsed or refractory setting consists of a single course.

• Gemtuzumab Ozogamicin 4.5 mg treatment can cause liver damage, including Veno-occlusive Liver Disease (VOD). Liver function needs to be assessed regularly. Symptoms of liver toxicity or VOD, such as jaundice or pain in the abdomen, warrant discontinuation of treatment.
• Infusion-related reactions (IRRs), including anaphylaxis, may arise. Monitor patients throughout the infusion for signs of allergic reactions, such as chills, fever, rash, or difficulty breathing. If severe, stop the infusion and start appropriate treatment.
• Treatment with this therapeutic drug may increase the probability of bleeding. Monitor for signs of hemorrhage, including blood in stools, easy bruising, or unexplained bleeding. Patients should be carefully monitored for any symptomps of bleeding throughout the treatment.
• This medicine may cause QT interval prolongation. This can increase the risk of arrhythmias. Regular ECG monitoring is required, particularly in those with a known history of heart complications or those using other QT-prolonging medicines.
• This medicinal product is not recommended for individuals with acute myeloid leukemia (AML) who have adverse-risk cytogenetics. Treatment may not be as promising, and the risks may outweigh the benefits in these patients.
• Gemtuzumab Ozogamicin 4.5 mg injection may harm a developing fetus. Pregnant women or those planning pregnancy should not use this medicine. Use an effective contraception method during treatment and for at least six months after the final dose.

Indian Pharma Network is able to source MYLOTARG (Cancer Treatment Medicines) from across the globe, and has ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to Patient’s address only from New Delhi, India.

What documents are required to import MYLOTARG to India?

MYLOTARG (gemtuzumab ozogamicin) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is MYLOTARG available in India?

MYLOTARG (gemtuzumab ozogamicin injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Mylotarg in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

MYLOTARG can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of MYLOTARG (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Mylotarg 4.5 mg injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Mylotarg®?

Gemtuzumab ozogamicin is a Generic Name for the trade name drug Mylotarg®.

What is the Manufacturer’s Name of Mylotarg®?

Mylotarg® is manufactured by Wyeth Pharmaceuticals LLC.

Is Mylotarg approved by the FDA?

Yes, Mylotarg® is approved by the FDA. Date of first approval: September 1, 2017.

What is the dosage and form of Mylotarg® supplied?

Mylotarg® is supplied for Injection: 4.5 mg as a lyophilized cake or powder in a single-dose vial for reconstitution and dilution for intravenous (IV) use.

What are the most common side effects of Mylotarg® 4.5 mg injections? 

The most common side effects of Mylotarg® injection are fever, nausea, hemorrhage, mucositis, infection, rash, vomiting, constipation, headache, increased AST, febrile neutropenia, increased ALT, and decreased appetite.

How much does Mylotarg® 4.5 mg injection cost in India?

Prices of Mylotarg injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Mylotarg 4.5 mg injection cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Mylotarg® 4.5 mg injections be available in SAARC countries? 

Apart from Gulf countries, Mylotarg® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Mylotarg® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Mylotarg® 4.5 mg injections online in India?

Yes, one can buy Mylotarg 4.5 mg online in India and other countries at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Mylotarg® injections through legal channels. 

What are the storage conditions of Mylotarg® 4.5 mg injections?

Refrigerate (2 to 8°C; 36 to 46°F) vials and store in the original carton to protect from light. It is not advisable to freeze this medicinal product.